CLV Frontiers' cannabis-inspired terpene beers launch in London

|

Published 09-OCT-2018 12:39 P.M.

|

4 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

CLV Frontier Brands — a joint venture between Creso Pharma (ASX:CPH), LGC Capital (TSXV:LG), and UK-based Baltic Beer Company — has now officially kicked off the global launch of its cannabis-inspired terpenes-infused Old Boy Mary Jane (OBMJ) beer range, beginning with the UK leg at the Boutique Bar show in London last week.

As CPH revealed in a market update this morning, the OBMJ Big Egg Mountain Baltic Porter won a silver medal at the Baltic Beer Star 2018 competition that was held in Riga earlier this month. OBMJ Improper Pils and Ghost Bog Hazy IPA both won Bronze Medals.

The award-winning beers

The launch of OBMJ Ghost Bog Hazy IPA, OBMJ Improper Pils and OBMJ Big Egg Mountain Baltic Porter has all gone to plan, with wholesalers now appointed for the UK, and with two beers already listed on drinkshop.com and Beers of Europe.

The first two high-profile bars in London to take on OBMJ are Zigfrid Von Underbelly and Road trip & Workshop.

The mainland European launch will be at Bar Convent in Berlin, starting this week.

Old Boy Mary Jane beers contain blends of organic essential oils called terpenes that give cannabis its distinctive aroma and flavour. The terpenes used in the beer carry the unmistakable fragrance and flavour of marijuana, but they aren’t derived from it. They also don’t contain THC (tetrahydrocannabinol) — the compound found in cannabis that gets you high.

This global launch also comes with impeccable timing, as the popularity of both cannabis-infused beverages and craft beer in general continue to surge.

The JV will be following in the footsteps of the brewing giant behind Corona beer, Constellation Brands (NYSE:STZ), which recently invested US$4 billion into Ontario-based Canopy Growth (NYSE:CGC | TSX:WEED). Canopy Growth has since become the first pure-play cannabis stock whose valuation has entered the large-cap corridor (that is, with a market cap of at least $10 billion).

Molson Coors Brewing Company (NYSE:TAP) is another alcohol giant that has invested heavily in developing cannabis-infused beverages. UK spirits giant, Diageo (of Guinness beer fame), is also in discussion with at least three Canadian cannabis producers about a possible deal.

In short, the intermingling of cannabis and beer is very much on theme right now. More broadly, the craft beer market itself is also blossoming, and will grow by 5% over the next five years, according to IBIS.

According to Grand View Research, the global craft beer market is expected to reach US$502.9 billion by 2025 on the back of rising demand for low alcohol by volume and flavoured beer.

John McMullen, CEO of LGC and director of CLV, said that the global launch of OBMJ beers in London has been very successful, and that interest levels in these unique beers has exceeded original expectations.

“The global beverage market has been expanding rapidly into the craft beverage lines. With highly individualised and independent young adults demanding a high-end selection of beverages to choose from, CLV caters to this growing market and provides a connection with flavours and experiences that the global consumer can fully enjoy,” McMullen said.

Creso co-founder and CEO and CLV director, Dr. Miri Halperin Wernli, commented: “We are very excited about the launch of these unique creative products infused with natural organic blends that bring exciting flavours and aromas.

“We see a lot of potential value in this growing market and anticipate a successful initial portfolio launch in Europe. Through the vast geographic reach of the three parties in this venture, we can look forward to opportunities for this innovative new range of drinks to be produced and sold globally.”

Paul Baxendale, managing director and sales and marketing director at Baltic Beer Company, said: “We were delighted with the success of the OBMJ launch in London. The liquids were really well received and response to the branding was extremely positive.

“There was a much greater level of understanding in relation to these unique beers than we expected, and we are confident that OBMJ can secure a prominent place in the market. We now move to launch the OBMJ brand in Germany,” Baxendale added.

This positive piece of news from the quick-footed CPH comes only a day after the company’s last update. Yesterday, CPH announced that its application to become a licenced cannabis producer (via its Canadian subsidiary, Mernova Medicinal Inc.) has been accepted by Health Canada.

This will transpire in a cultivation licence — one of the few to be issued to local companies in Nova Scotia — which will see Mernova planting its first cannabis crop in the new Canadian cutting-edge indoor growing facility at the end of the year.

It should be noted that CPH is in its early stages and investors should seek professional financial advice if considering this stock for their portfolio.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X